- Global Pharma News & Resources

Gastrointestinal Drugs Market To Develop Significantly by 2025 – Zion Market Research

Gastrointestinal (GI) syndrome/disease affects particularly in stomach, pancreas, rectum and large intestine, esophagus, small intestine, gallbladder, and liver. The main symptoms of gastrointestinal (GI) diseases/syndrome are indigestion, heartburn, constipation bloating, and so on. According to the World Gastroenterology Organization, it is estimated that around 30-35% of the total population is being affected by chronic GI or acute complication.

Global Gastrointestinal Drugs Market: Growth Factors

The growing occurrence of gastrointestinal diseases all over the world is the major aspect of the development of the gastrointestinal drugs market. On the other hand, the growing investments, particularly in research activities for the expansion and development of these drugs, and the increasing knowledge about the accessibility of the healing process and treatments are adding significantly to the expansion of gastrointestinal drugs market. Furthermore, the technological developments in the treatment process are projected to propel this market outstandingly in the coming years. Rising number of patients suffering from GI disorders, owing to alter in the dietary plan also positively affects the growth of the gastrointestinal drugs market.

Global Gastrointestinal Drugs Market: Segmentation

The global gastrointestinal drugs market is categorized based on the route of administration, drug category, by end users, and disease type. Based on drug category, the gastrointestinal drugs market is divided into antiemetic, acid neutralizers, anti-inflammatory, laxatives & antidiarrheal, and others. Based on route of administration, the division incorporates, parental, rectal, and oral. Based on disease type, the market is divided into inflammatory bowel diseases, gastroesophageal reflux diseases, and others. The end user division of gastrointestinal drugs market comprises retail pharmacies, hospital pharmacies, and others.

Get Free Sample of this Research Report

Global Gastrointestinal Drugs Market: Regional Analysis

It is projected that North America has come up as the most important regional market for gastrointestinal drugs globally. Due to the existence of customer-friendly reimbursement policies for the treatment/healing of chronic syndrome/diseases, it is projected to attain a major share in the coming years for the gastrointestinal drugs market. North America is expected to retain its dominance in the gastrointestinal drugs market owing to the growing number of aged population, who are mainly prone to gastrointestinal syndromes/diseases.

Europe is anticipated to hold the significant position after North America in the global gastrointestinal drugs market. The introduction of biosimilars for particularly patent-confined brands accessible for the healing of inflammatory bowel syndrome/disease works in favor of the gastrointestinal drugs market, particularly in Europe. Asia Pacific is projected to hold the most profitable market for the global gastrointestinal drugs. The enhancement of the healthcare and medical infrastructure, increase in public and private investments for the technological advancements and life sciences research in the treatments and healing process of gastrointestinal syndromes/diseases in up-coming economies, such as China and India, are anticipated to fuel the global gastrointestinal drugs market in Asia Pacific in the coming years.

Global Gastrointestinal Drugs Market: Competitive Players

Some of the most important market players in the global gastrointestinal drugs market are Allergan Plc., Abbott Laboratories, Bayer AG, AstraZeneca, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH., Sanofi, Janssen Biotech Inc., Valeant Pharmaceuticals Inc., and Takeda Pharmaceutical, among others.

Get TOC of this Research Report

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 17-Aug-2020